CU22629A1 - Formulaciones inmunopotenciadoras para uso vacunal - Google Patents
Formulaciones inmunopotenciadoras para uso vacunalInfo
- Publication number
- CU22629A1 CU22629A1 CU1997027A CU1997027A CU22629A1 CU 22629 A1 CU22629 A1 CU 22629A1 CU 1997027 A CU1997027 A CU 1997027A CU 1997027 A CU1997027 A CU 1997027A CU 22629 A1 CU22629 A1 CU 22629A1
- Authority
- CU
- Cuba
- Prior art keywords
- formulation
- elements
- decrease
- immune response
- respect
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención está relacionada con la rama de la medicina, particularmente con un nuevo adyuvante que permita la potenciación de la respuesta inmune a antígenos vacunales. El objetivo técnico que se persigue con la invención propuesta es precisamente el desarrollo de una formulación capaz de elevar los niveles de respuesta inmune del organismo a antígenos vacunales con el uso de elementos de un alto grado de pureza y que presentan una actividad sinérgica en dicha formulación. Para lograr este objetivo se emplea esencialmente una combinación de dos elementos: una sal de calcio, preferentemente el oxalato de calcio quimícamente puro y un polisacárido inmunoestimulante preferentemente el polisacárido del gel de Aloe barbadensis Miller. Otros elementos, reguladores del tamano de la partícula de oxalato de calcio, pueden ser introducidos en la formulación. La formulación objeto de esta invención, permite obtener elevadas respuestas de anticuerpos, evidenciando una actividad sinérgica reportada por primera vez entre dichas partículas y el inmunoestimulante. La diferencia entre el poder adyuvante de la formulación con respecto a los elementos por separado, es amplia. La formulación objeto de la presente invención es aplicable en la industria farmaceútica, para la elaboración de vacunas tanto para uso en humanos como en animales, a las que les confiere una mayor inmunogenicidad, permitiendo disminuir el número de inyecciones, disminuir la cantidad de antígeno por dosis y potenciar la respuesta de mucosas cuando es usada por esta vía. Además, la formulación en cuestión es factible en cualquier situación donde se desee introducir antígenos, tanto por vía mucosal como sistémica, aprovechando el vehículo o sistema particulado y las propiedades adhesivas de este compuesto con respecto a las células epiteliales.
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1997027A CU22629A1 (es) | 1997-03-06 | 1997-03-06 | Formulaciones inmunopotenciadoras para uso vacunal |
MYPI98000960A MY132817A (en) | 1997-03-06 | 1998-03-05 | Formulations for immunological potentiation of vaccines |
AT98907815T ATE295182T1 (de) | 1997-03-06 | 1998-03-05 | Zusammensetzungen zur immunverstärkung von impfstoffen |
PCT/CU1998/000003 WO1998039032A1 (es) | 1997-03-06 | 1998-03-05 | Formulaciones inmunopotenciadoras para uso vacunal |
AU66077/98A AU6607798A (en) | 1997-03-06 | 1998-03-05 | Immunopotentiating formulations for vaccinal use |
BR9808832-7A BR9808832A (pt) | 1997-03-06 | 1998-03-05 | Formulações de vacina para uso nasofarìngeo, uso mucosal e uso sistêmico |
EP98907815A EP0971737B1 (en) | 1997-03-06 | 1998-03-05 | Immunopotentiating formulations for vaccinal use |
CNB988041456A CN1161154C (zh) | 1997-03-06 | 1998-03-05 | 用于疫苗的免疫增强制剂 |
DE69830156T DE69830156T2 (de) | 1997-03-06 | 1998-03-05 | Zusammensetzungen zur immunverstärkung von impfstoffen |
US09/380,790 US6355414B1 (en) | 1997-03-06 | 1998-03-05 | Immunopotentiating formulations for vaccinal use |
ZA981897A ZA981897B (en) | 1997-03-06 | 1998-03-05 | Formualtions for immunological potentiation of vaccines |
ES98907815T ES2241122T3 (es) | 1997-03-06 | 1998-03-05 | Formulaciones de inmunopotenciacion para uso como vacunas. |
CA002283344A CA2283344A1 (en) | 1997-03-06 | 1998-03-05 | Immunopotentiating formulations for vaccinal use |
ARP980101012A AR009866A1 (es) | 1997-03-06 | 1998-03-06 | Formulacion inmunopotenciadora para uso vacunal |
HK00105771A HK1026626A1 (en) | 1997-03-06 | 2000-09-14 | Immunopotentiating formulations for vaccinal use. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1997027A CU22629A1 (es) | 1997-03-06 | 1997-03-06 | Formulaciones inmunopotenciadoras para uso vacunal |
Publications (1)
Publication Number | Publication Date |
---|---|
CU22629A1 true CU22629A1 (es) | 2000-12-22 |
Family
ID=5459228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU1997027A CU22629A1 (es) | 1997-03-06 | 1997-03-06 | Formulaciones inmunopotenciadoras para uso vacunal |
Country Status (15)
Country | Link |
---|---|
US (1) | US6355414B1 (es) |
EP (1) | EP0971737B1 (es) |
CN (1) | CN1161154C (es) |
AR (1) | AR009866A1 (es) |
AT (1) | ATE295182T1 (es) |
AU (1) | AU6607798A (es) |
BR (1) | BR9808832A (es) |
CA (1) | CA2283344A1 (es) |
CU (1) | CU22629A1 (es) |
DE (1) | DE69830156T2 (es) |
ES (1) | ES2241122T3 (es) |
HK (1) | HK1026626A1 (es) |
MY (1) | MY132817A (es) |
WO (1) | WO1998039032A1 (es) |
ZA (1) | ZA981897B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7011845B2 (en) * | 2000-05-09 | 2006-03-14 | Mcp Hahnemann University | β-glucans encapsulated in liposomes |
CU23011A1 (es) * | 2000-11-03 | 2004-12-17 | Ct Ingenieria Genetica Biotech | Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones |
CU23031A1 (es) * | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
US20060105063A1 (en) * | 2004-11-18 | 2006-05-18 | Kent Hann | Synergic combination of compositions containing aloe vera isolates and their therapeutic application |
AU2006238906B2 (en) | 2005-04-25 | 2013-04-11 | Cadila Pharmaceuticals Ltd. | Vaccine adjuvants |
CA2672338C (en) | 2006-12-15 | 2017-06-06 | National Research Council Of Canada | Archaeal polar lipid aggregates for administration to animals |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5106616A (en) * | 1988-01-14 | 1992-04-21 | Carrington Laboratories, Inc. | Administration of acemannan |
US5308838A (en) * | 1982-05-07 | 1994-05-03 | Carrington Laboratories, Inc. | Uses of aloe products |
ATE99331T1 (de) * | 1989-09-08 | 1994-01-15 | Takeda Chemical Industries Ltd | Fusionsproteine und herstellung davon. |
ZA93216B (en) * | 1992-01-17 | 1993-08-18 | Solvay Animal Health Inc | Vaccine containing acemannan as an adjuvant. |
SK280702B6 (sk) * | 1992-05-23 | 2000-06-12 | Smithkline Beecham Biologicals S. A. | Kombinovaný očkovací prostriedok obsahujúci povrch |
AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
JPH08183742A (ja) * | 1994-12-28 | 1996-07-16 | Dai Ichi Seiyaku Co Ltd | 経鼻ワクチンリポソーム |
JP3098401B2 (ja) * | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
-
1997
- 1997-03-06 CU CU1997027A patent/CU22629A1/es unknown
-
1998
- 1998-03-05 US US09/380,790 patent/US6355414B1/en not_active Expired - Fee Related
- 1998-03-05 AU AU66077/98A patent/AU6607798A/en not_active Abandoned
- 1998-03-05 BR BR9808832-7A patent/BR9808832A/pt not_active Application Discontinuation
- 1998-03-05 ES ES98907815T patent/ES2241122T3/es not_active Expired - Lifetime
- 1998-03-05 WO PCT/CU1998/000003 patent/WO1998039032A1/es active IP Right Grant
- 1998-03-05 ZA ZA981897A patent/ZA981897B/xx unknown
- 1998-03-05 EP EP98907815A patent/EP0971737B1/en not_active Expired - Lifetime
- 1998-03-05 AT AT98907815T patent/ATE295182T1/de not_active IP Right Cessation
- 1998-03-05 DE DE69830156T patent/DE69830156T2/de not_active Expired - Fee Related
- 1998-03-05 CN CNB988041456A patent/CN1161154C/zh not_active Expired - Fee Related
- 1998-03-05 CA CA002283344A patent/CA2283344A1/en not_active Abandoned
- 1998-03-05 MY MYPI98000960A patent/MY132817A/en unknown
- 1998-03-06 AR ARP980101012A patent/AR009866A1/es unknown
-
2000
- 2000-09-14 HK HK00105771A patent/HK1026626A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA981897B (en) | 1998-09-07 |
DE69830156D1 (de) | 2005-06-16 |
EP0971737A1 (en) | 2000-01-19 |
DE69830156T2 (de) | 2006-01-26 |
CN1252002A (zh) | 2000-05-03 |
CA2283344A1 (en) | 1998-09-11 |
BR9808832A (pt) | 2000-07-04 |
WO1998039032A1 (es) | 1998-09-11 |
AU6607798A (en) | 1998-09-22 |
HK1026626A1 (en) | 2000-12-22 |
ATE295182T1 (de) | 2005-05-15 |
MY132817A (en) | 2007-10-31 |
ES2241122T3 (es) | 2005-10-16 |
AR009866A1 (es) | 2000-05-03 |
US6355414B1 (en) | 2002-03-12 |
EP0971737B1 (en) | 2005-05-11 |
CN1161154C (zh) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2331952T3 (es) | Fraccion de quil a con baja toxicidad y su uso. | |
AU648509B2 (en) | Stable vaccine compositions containing interleukins | |
YU28392A (sh) | Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a | |
DE69115514T2 (de) | Liposomenhaltige intranasale Impfstofformulierung | |
DE69628834D1 (de) | Virus impfstoff | |
Zhang et al. | A protein vaccine with Alum/c-GAMP/poly (I: C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern | |
CU22629A1 (es) | Formulaciones inmunopotenciadoras para uso vacunal | |
Hassan et al. | Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems | |
ES2645076T3 (es) | Adyuvante | |
ES2894138T3 (es) | Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes | |
ES2079851T3 (es) | Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas. | |
ES2329118T3 (es) | Ltb4 como adyuvante de vacuna. | |
MXPA03009515A (es) | Vacunas que incluyen como adyuvante ifn del tipo i, y procesos relacionados con ellas. | |
ES2938847T3 (es) | Composiciones para la inducción de la respuesta inmunitaria | |
NZ250555A (en) | Vaccine with enhanced immunogenicity by inclusion of a cytokine | |
ES2082201T3 (es) | Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos. | |
AR020403A1 (es) | Formulacion de acidos nucleicos y acemanano | |
Phillips et al. | Modulation of murine macrophage nitric oxide synthesis by liposomal phospholipids: correlation with liposome immune adjuvant activity | |
BR9306187A (pt) | Vacina bacterin-toxóide pasteurella haemolytica tipo a-1 | |
KR20010040932A (ko) | 인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신 | |
Ngu | Human cancers and viruses: A hypothesis for immune destruction of tumours caused by certain enveloped viruses using modified viral antigens | |
Kimoto et al. | Induction of systemic, mucosal and cellular immunity against SARS-CoV-2 in mice intratracheally vaccinated with a viral S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10 | |
Bexiga et al. | Carboxymethyl chitosan (CMCS) nanoparticles for mucosal vaccination against rabies: evaluation of the immune response following oral immunization studies in mice | |
Vicente et al. | A Polymer | |
Vicente Ozores et al. | A Polymer/Oil Based Nanovaccine as a Single-Dose Immunization Approach |